Beta Blockers in Chronic Kidney Disease

Introduction to Beta Blockers in CKD

The American College of Cardiology recommends beta-blockers as add-on therapy for blood pressure control in CKD patients, particularly when compelling cardiovascular indications exist, such as post-myocardial infarction, heart failure with reduced ejection fraction, or coronary artery disease 1, 2

The American Heart Association recommends ACE inhibitors or ARBs as first-line antihypertensive agents in CKD, particularly when albuminuria ≥300 mg/g creatinine is present, due to proven benefits in slowing CKD progression and reducing cardiovascular events 1, 2

The American College of Cardiology recommends beta-blockers (specifically carvedilol, metoprolol succinate, or bisoprolol) as mandatory guideline-directed medical therapy to reduce mortality and sudden cardiac death in patients with post-myocardial infarction or acute coronary syndrome 3, 4
The Heart Failure Society of America recommends beta-blockers proven to reduce mortality (bisoprolol, carvedilol, metoprolol succinate) as essential regardless of CKD stage, though careful monitoring for bradycardia and hypotension is required 3, 5
The American College of Cardiology recommends beta-blockers to reduce angina, improve exercise tolerance, and reduce cardiovascular events in patients with stable ischemic heart disease with angina 3, 6

The Journal of the American College of Cardiology states that beta-blockers are effective antihypertensive agents and are NOT contraindicated in CKD or peripheral arterial disease 7
The American College of Cardiology recommends adding beta-blockers as second- or third-line therapy after ACE inhibitors/ARBs, particularly when compelling cardiac indications exist, to achieve a target blood pressure of <130/80 mmHg 1, 6

The American Heart Association recommends carvedilol as the preferred beta-blocker in CKD due to its vasodilating properties from alpha-1 blockade, which preserves renal blood flow and glomerular filtration rate better than cardioselective agents 3

The American College of Cardiology recommends starting with low doses and titrating gradually to minimize hypotension, bradycardia, and fluid retention, and assessing renal function within 2-4 weeks of starting or increasing doses 5, 2, 8

The American Journal of Kidney Diseases recommends beta-blockers in hemodialysis patients with previous myocardial infarction or established coronary artery disease, as they are associated with decreased mortality 4
The American College of Cardiology recommends targeting pre-dialysis blood pressure at 140/90 mmHg, provided no substantial orthostatic hypotension or intradialytic hypotension occurs 4

The American College of Cardiology recommends combining beta-blockers with ACE inhibitors/ARBs in CKD patients with heart failure or post-MI, as this combination reduces mortality more effectively than either agent alone 5, 3
The American College of Cardiology recommends adding diuretics (loop diuretics in advanced CKD) for volume management, and avoiding the triple combination of ACE inhibitor + ARB + aldosterone antagonist due to increased adverse events without additional benefit 8, 3, 2